European Child & Adolescent Psychiatry

, Volume 16, Issue 1, pp 33–47 | Cite as

The QT interval and psychotropic medications in children

Recommendations for clinicians


The use of psychotropic medications in children has increased significantly in the last few years. There have been several case reports of sudden death in children taking specific psychotropic medications. Fears that these deaths might have been caused by ventricular arrhythmias have been enhanced by reports of electrocardiographic abnormalities, including prolongation of the QTc interval, in patients taking these medications. Several factors including genetic susceptibility, pre-existing cardiac disease, abnormalities of drug clearance and concomitant use of other medications known to affect the QTc interval can increase the susceptibility of the heart to conduction abnormalities. This article discusses the potential of particular psychotropic drugs to prolong the QTc interval in children, and examines other factors that may contribute to conduction abnormalities. We aim to provide clear clinical recommendations for the prescription of these drugs and the monitoring of children taking them.


psychotropic medications QTc prolongation arrhythmia prescribing children 


  1. 1.
    (1996) Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs. Pediatrics 98:143–145Google Scholar
  2. 2.
    (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536Google Scholar
  3. 3.
    Alderman J (2005) Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin Ther 27:1050–1063PubMedCrossRefGoogle Scholar
  4. 4.
    Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatr 159:1337–1346PubMedCrossRefGoogle Scholar
  5. 5.
    Amitai Y, Frischer H (2006) Excess fatality from desipramine in children and adolescents. J Am Acad Child Adolesc Psychiatr 45:54–60CrossRefGoogle Scholar
  6. 6.
    Amital D, Amital H, Gross R, Kindler S, Zohar J (1994) Sinus bradycardia due to fluvoxamine overdose. Br J Psychiatr 165:553–554Google Scholar
  7. 7.
    Aronson MD, Hafez H (1986) A case of trazodone-induced ventricular tachycardia. J Clin Psychiatr 47:388–389Google Scholar
  8. 8.
    Balit CR, Isbister GK, Hackett LP, Whyte IM (2003) Quetiapine poisoning: a case series. Ann Emerg Med 42:751–758PubMedCrossRefGoogle Scholar
  9. 9.
    Bauchner H (2000) ADHD: a new practice guideline from the American Academy of Pediatrics. Attention deficit hyperactive disorder. Arch Dis Child 83:63PubMedCrossRefGoogle Scholar
  10. 10.
    Biederman J (1991) Sudden death in children treated with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatr 30:495–498CrossRefGoogle Scholar
  11. 11.
    Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL (2003) Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 41:101–104PubMedCrossRefGoogle Scholar
  12. 12.
    Blair J, Scahill L, State M, Martin A (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatr 44:73–79CrossRefGoogle Scholar
  13. 13.
    Blumer JL (1999) Off-label uses of drugs in children. Pediatrics 104:598–602PubMedGoogle Scholar
  14. 14.
    Bonati M, Clavenna A (2005) The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatr 17:181–188CrossRefGoogle Scholar
  15. 15.
    Bont L, Bosker HA, Brus F, Yska JP, Bosch FH (1998) Torsade de pointes after pipamperone intoxication. Pharm World Sci 20:137PubMedCrossRefGoogle Scholar
  16. 16.
    Bramble D (1997) Psychostimulants and British Child Psychiatrists. Child Psychol Psychiatr Rev 2:159–162Google Scholar
  17. 17.
    Bryant SM, Zilberstein J, Cumpston KL, Magdziarz DD, Costerisan DD (2003) A case series of ziprasidone overdoses. Vet Hum Toxicol 45:81–82PubMedGoogle Scholar
  18. 18.
    Catalano G, Catalano MC, Nunez CY, Walker SC (2001) Atypical antipsychotic overdose in the pediatric population. J Child Adolesc Psychopharmacol 11:425–434PubMedCrossRefGoogle Scholar
  19. 19.
    Chalumeau M, Treluyer JM, Salanave B, Assathiany R, Cheron G, Crocheton N, Rougeron C, Mares M, Breart G, Pons G (2000) Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 83:502–505PubMedCrossRefGoogle Scholar
  20. 20.
    Chandran KS (1994) ECG and clonidine. J Am Acad Child Adolesc Psychiatr 33:1351–1352CrossRefGoogle Scholar
  21. 21.
    Chiu CC, Chang WH, Huang MC, Chiu YW, Lane HY (2005) Regular-dose risperidone on QTc intervals. J Clin Psychopharmacol 25:391–393PubMedCrossRefGoogle Scholar
  22. 22.
    Citak A, Soysal DD, Ucsel R, Karabocuoglu M, Uzel N (2002) Efficacy of long duration resuscitation and magnesium sulphate treatment in amitriptyline poisoning. Eur J Emerg Med 9:63–66PubMedCrossRefGoogle Scholar
  23. 23.
    Cohen H, Loewenthal U, Matar M, Kotler M (2001) Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatr 179:167–171CrossRefGoogle Scholar
  24. 24.
    Combes A, Peytavin G, Theron D (2001) Conduction disturbances associated with venlafaxine. Ann Intern Med 134:166–167PubMedGoogle Scholar
  25. 25.
    Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795–803PubMedCrossRefGoogle Scholar
  26. 26.
    Curtis LH, Masselink LE, Ostbye T, Hutchison S, Dans PE, Wright A, Krishnan RR, Schulman KA (2005) Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med 159:362–366PubMedCrossRefGoogle Scholar
  27. 27.
    Czekalla J, Beasley Jr CM, Dellva MA, Berg PH, Grundy S (2001) Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatr 62:191–198CrossRefGoogle Scholar
  28. 28.
    Dallaire S (2001) Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval. CMAJ 164:91, 95PubMedGoogle Scholar
  29. 29.
    de Boer RA, van Dijk TH, Holman ND, van Melle JP (2005) QT interval prolongation after sertraline overdose: a case report. BMC Emerg Med 5:5PubMedCrossRefGoogle Scholar
  30. 30.
    de Meester A, Carbutti G, Gabriel L, Jacques JM (2001) Fatal overdose with trazodone: case report and literature review. Acta Clin Belg 56:258–261PubMedGoogle Scholar
  31. 31.
    Dineen S, Withrow K, Voronovitch L, Munshi F, Nawbary MW, Lippmann S (2003) QTc prolongation and high-dose olanzapine. Psychosomatics 44:174–175PubMedCrossRefGoogle Scholar
  32. 32.
    Donmez O, Cetinkaya M, Canbek R (2005) Hemoperfusion in a child with amitriptyline intoxication. Pediatr Nephrol 20:105–107PubMedCrossRefGoogle Scholar
  33. 33.
    dosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL (2005) Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 15:68–77PubMedCrossRefGoogle Scholar
  34. 34.
    Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J (2001) Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther 6:255–260PubMedGoogle Scholar
  35. 35.
    Dubnov G, Fogelman R, Merlob P (2005) Prolonged QT interval in an infant of a fluoxetine treated mother. Arch Dis Child 90:972–973PubMedCrossRefGoogle Scholar
  36. 36.
    Durst R, Rosca-Rebaudengo P, Admon D (1994) Phenothiazine-associated supraventricular tachycardia. Aust NZ J Psychiatr 28:333–336Google Scholar
  37. 37.
    Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance AL, Tyl Y, Luk ES (2003) Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 111:372–375PubMedCrossRefGoogle Scholar
  38. 38.
    Erfurth A, Loew M, Dobmeier P, Wendler G (1998) [ECG changes after paroxetine. 3 case reports]. Nervenarzt 69:629–631PubMedCrossRefGoogle Scholar
  39. 39.
    Finlayson K, Witchel HJ, McCulloch J, Sharkey J (2004) Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 500:129–142PubMedCrossRefGoogle Scholar
  40. 40.
    Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ (2000) Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 20:317–324PubMedCrossRefGoogle Scholar
  41. 41.
    Gbadebo TD, Trimble RW, Khoo MS, Temple J, Roden DM, Anderson ME (2002) Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 105:770–774PubMedCrossRefGoogle Scholar
  42. 42.
    Gesell LB, Stephen M (2005) Toxicity following a single dose of risperidone for pediatric attention deficit hyperactivity disorder. J Toxicol Clin Toxicol 35:549Google Scholar
  43. 43.
    Gluais P, Bastide M, Grandmougin D, Fayad G, Adamantidis M (2004) Risperidone reduces K+ currents in human atrial myocytes and prolongs repolarization in human myocardium. Eur J Pharmacol 497:215–222PubMedCrossRefGoogle Scholar
  44. 44.
    Goodnick PJ, Jerry J, Parra F (2002) Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 3:479–498PubMedCrossRefGoogle Scholar
  45. 45.
    Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 99:979–982PubMedGoogle Scholar
  46. 46.
    Guy JM, Ndre-Fouet X, Porte J, Bertrand M, Lamaud M, Verneyre H (1991) [Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol]. Ann Cardiol Angeiol (Paris) 40:541–545Google Scholar
  47. 47.
    Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649–1671PubMedCrossRefGoogle Scholar
  48. 48.
    Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24:62–69PubMedCrossRefGoogle Scholar
  49. 49.
    Hewer W, Rost W, Gattaz WF (1995) Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatr Clin Neurosci 246:1–6CrossRefGoogle Scholar
  50. 50.
    Hochberg HM, Kanter D, Houser VP (1995) Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Pharmacopsychiatry 28:253–256PubMedGoogle Scholar
  51. 51.
    Hoehns JD, Fouts MM, Kelly MW, Tu KB (2001) Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 35:862–866PubMedCrossRefGoogle Scholar
  52. 52.
    Hoehns JD, Stanford RH, Geraets DR, Skelly KS, Lee HC, Gaul BL (2001) Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy 21:871–883PubMedCrossRefGoogle Scholar
  53. 53.
    Horrigan JP, Barnhill LJ, Courvoisie HE (1997) Olanzapine in PDD. J Am Acad Child Adolesc Psychiatr 36:1166–1167CrossRefGoogle Scholar
  54. 54.
    Hunt N, Stern TA (1995) The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Psychosomatics 36:541–549PubMedGoogle Scholar
  55. 55.
    Isbister GK, Balit CR (2003) Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 37:999–1002PubMedCrossRefGoogle Scholar
  56. 56.
    Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42:277–285PubMedCrossRefGoogle Scholar
  57. 57.
    Isbister GK, Hackett LP (2003) Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. J Toxicol Clin Toxicol 41:167–173PubMedCrossRefGoogle Scholar
  58. 58.
    Isbister GK, Prior FH, Foy A (2001) Citalopram-induced bradycardia and presyncope. Ann Pharmacother 35:1552–1555PubMedCrossRefGoogle Scholar
  59. 59.
    Jackson T, Ditmanson L, Phibbs B (1997) Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157:2013–2015PubMedCrossRefGoogle Scholar
  60. 60.
    Jensen BT, Larroude CE, Rasmussen LP, Holstein-Rathlou NH, Hojgaard MV, Agner E, Kanters JK (2004) Beat-to-beat QT dynamics in healthy subjects. Ann Noninvasive Electrocardiol 9:3–11PubMedCrossRefGoogle Scholar
  61. 61.
    Jervell A, Lange Nielsen F (1957) Congenital deaf-mutism, functional heart disease with prolongation of the Q–T interval and sudden death. Am Heart J 54:59–68PubMedCrossRefGoogle Scholar
  62. 62.
    Kang J, Chen XL, Rampe D (2001) The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel. Biochem Biophys Res Commun 286:499–504PubMedCrossRefGoogle Scholar
  63. 63.
    Kautzner J, Yi G, Camm AJ, Malik M (1994) Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol 17:928–937PubMedCrossRefGoogle Scholar
  64. 64.
    Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 42:67–71PubMedCrossRefGoogle Scholar
  65. 65.
    Kewley GD (1999) Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatr 38:1327–1328CrossRefGoogle Scholar
  66. 66.
    Krentz AJ, Mikhail S, Cantrell P, Hill GM (2001) Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine. BMJ 322:1213PubMedCrossRefGoogle Scholar
  67. 67.
    Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y (1990) Haloperidol-induced torsades de pointes. Chest 98:482–484PubMedGoogle Scholar
  68. 68.
    Krulewicz S, Carpenter DJ, Fong R, Horrigan JP, Lipschitz A, Perera P, Wagner KD (2006) Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatr 45:422–430CrossRefGoogle Scholar
  69. 69.
    Kurth J, Maguire G (2004) Pediatric case report of quetiapine overdose and QTc prolongation. Ann Clin Psychiatr 16:229–231Google Scholar
  70. 70.
    Labellarte MJ, Crosson JE, Riddle MA (2003) The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatr 42:642–650CrossRefGoogle Scholar
  71. 71.
    Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC (1993) Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatr 54:224–228Google Scholar
  72. 72.
    Landes GM, Curran ME, Keating MT (1995) Molecular characterization and refined genomic localization of three human potassium ion channel genes. Cytogenet Cell Genet 70:280–284PubMedCrossRefGoogle Scholar
  73. 73.
    Langlois RP, Paquette D (1994) Sustained bradycardia during fluvoxamine and buspirone intoxication. Can J Psychiatr 39:126–127Google Scholar
  74. 74.
    Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220PubMedCrossRefGoogle Scholar
  75. 75.
    Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F (2006) QT interval prolongation associated with venlafaxine administration. Int J Cardiol 109:116–117PubMedCrossRefGoogle Scholar
  76. 76.
    Levenson JL (1999) Prolonged QT interval after trazodone overdose. Am J Psychiatr 156:969–970PubMedGoogle Scholar
  77. 77.
    Lin CH, Chen MC, Wang SY, Lin CY (2004) Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J Formos Med Assoc 103:437–441PubMedGoogle Scholar
  78. 78.
    Llerena A, Berecz R, Dorado P, de la Rubia A (2004) QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 18:189–193PubMedCrossRefGoogle Scholar
  79. 79.
    Lofton AL, Klein-Schwartz W (2005) Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila) 43:151–153Google Scholar
  80. 80.
    Maloney MJ, Schwam JS (1995) Clonidine and sudden death. Pediatrics 96:1176–1177PubMedGoogle Scholar
  81. 81.
    Mazur A, Strasberg B, Kusniec J, Sclarovsky S (1995) QT prolongation and polymorphous ventricular tachycardia associated with trasodone–amiodarone combination. Int J Cardiol 52:27–29PubMedCrossRefGoogle Scholar
  82. 82.
    McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321PubMedCrossRefGoogle Scholar
  83. 83.
    McNicholas F (2001) Prescribing practices of child psychiatrists in the UK. Child Adolesc Mental Health 6:166–171CrossRefGoogle Scholar
  84. 84.
    McNicholas F (2001) Psychotropic prescribing practices of paediatricians in the UK. Child Care Health Dev 27:497–508PubMedCrossRefGoogle Scholar
  85. 85.
    Michalets EL, Smith LK, Van Tassel ED (1998) Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32:761–765PubMedCrossRefGoogle Scholar
  86. 86.
    Michalets EL, Smith LK, Van Tassel ED (1998) Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32:761–765PubMedCrossRefGoogle Scholar
  87. 87.
    Moltedo JM, Porter GA, State MW, Snyder CS (2002) Sinus node dysfunction associated with lithium therapy in a child. Tex Heart Inst J 29:200–202PubMedGoogle Scholar
  88. 88.
    Nissen SE (2006) ADHD drugs and cardiovascular risk. N Engl J Med 354:1445–1448PubMedCrossRefGoogle Scholar
  89. 89.
    Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG (2005) QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 39:543–546PubMedCrossRefGoogle Scholar
  90. 90.
    O’Brien JM, Rockwood RP, Suh KI (1999) Haloperidol-induced torsade de pointes. Ann Pharmacother 33:1046–1050PubMedCrossRefGoogle Scholar
  91. 91.
    Ohtani H, Odagiri Y, Sato H, Sawada Y, Iga T (2001) A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs. Biol Pharm Bull 24:550–554PubMedCrossRefGoogle Scholar
  92. 92.
    Pappadopulos E, Intyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS (2003) Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatr 42:145–161CrossRefGoogle Scholar
  93. 93.
    Peano C, Leikin JB, Hanashiro PK (1997) Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine. Ann Emerg Med 30:704–708PubMedCrossRefGoogle Scholar
  94. 94.
    Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S (2000) Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth 47:251–254PubMedCrossRefGoogle Scholar
  95. 95.
    Pohl R, Bridges M, Rainey Jr JM, Boudoulas H, Yeragani VK (1986) Effects of trazodone and desipramine on cardiac rate and rhythm in a patient with preexisting cardiovascular disease. J Clin Psychopharmacol 6:380–381PubMedCrossRefGoogle Scholar
  96. 96.
    Popper C, Zimnitsky B (1995) Sudden-death putatively related to desipramine treatment in a youth: a fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol 5:283–300Google Scholar
  97. 97.
    Posey DJ, Walsh KH, Wilson GA, McDougle CJ (1999) Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 9:273–276PubMedGoogle Scholar
  98. 98.
    Rappley MD, Eneli IU, Mullan PB, Alvarez FJ, Wang J, Luo Z, Gardiner JC (2002) Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 23:23–30PubMedGoogle Scholar
  99. 99.
    Ravina T, Suarez ML, Mendez-Castrillon J (1998) Fluoxetine-induced QTU interval prolongation, T wave alternans and syncope. Int J Cardiol 65:311–313PubMedCrossRefGoogle Scholar
  100. 100.
    Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048–1052PubMedCrossRefGoogle Scholar
  101. 101.
    Riddle MA, Geller B, Ryan N (1993) Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatr 32:792–797CrossRefGoogle Scholar
  102. 102.
    Roden DM (1998) Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol 21:1029–1034PubMedCrossRefGoogle Scholar
  103. 103.
    Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013–1022PubMedCrossRefGoogle Scholar
  104. 104.
    Romano C, Gemme G, Pongiglione R (1963) [Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation. (Presentation of 1st case in Italian pediatric literature)]. Clin Pediatr (Bologna) 45:656–683Google Scholar
  105. 105.
    Rothenhausler HB, Hoberl C, Ehrentrout S, Kapfhammer HP, Weber MM (2000) Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatr 33:150–152CrossRefGoogle Scholar
  106. 106.
    Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM (2005) QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatr 4:1CrossRefGoogle Scholar
  107. 107.
    Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299–307PubMedCrossRefGoogle Scholar
  108. 108.
    Sawant S, Daviss SR (2004) Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatr 161:757PubMedCrossRefGoogle Scholar
  109. 109.
    Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135PubMedCrossRefGoogle Scholar
  110. 110.
    Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT (2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics 108:E25PubMedCrossRefGoogle Scholar
  111. 111.
    Schreier HA (1998) Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49–59PubMedGoogle Scholar
  112. 112.
    Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, Intyre Ii JC, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS (2003) Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatr 42:132–144CrossRefGoogle Scholar
  113. 113.
    Schwartz PJ, Moss AJ, Vincent GM, Crampton RS (1993) Diagnostic criteria for the long QT syndrome. An update. Circulation 88:782–784Google Scholar
  114. 114.
    Shah RR (2005) Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol 38:10–18PubMedCrossRefGoogle Scholar
  115. 115.
    Shah RR (2004) Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 36(Suppl 1):47–52PubMedCrossRefGoogle Scholar
  116. 116.
    Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatr 46:722–730PubMedGoogle Scholar
  117. 117.
    Shapiro LE, Shear NH (1999) Drug-drug interactions: how scared should we be? CMAJ 161:1266–1267PubMedGoogle Scholar
  118. 118.
    Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634–e641PubMedCrossRefGoogle Scholar
  119. 119.
    Shimizu W, Antzelevitch C (2000) Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 35:778–786PubMedCrossRefGoogle Scholar
  120. 120.
    Siddiqui MA, Khan IA (2004) Nefazodone-associated torsade de pointes. Int J Cardiol 93:85–86PubMedCrossRefGoogle Scholar
  121. 121.
    Slaveska K, Hollis C, Bramble D (1998) The use of antipsychotics by the child and adolescent psychiatrists. Psychiat Bull 22:685–687CrossRefGoogle Scholar
  122. 122.
    Spiller HA, Lintner CP, Winter ML (2005) Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother 39:1045–1048PubMedCrossRefGoogle Scholar
  123. 123.
    Stampfer H, Swanepoel P (2005) Severe tachycardia following low-dose clozapine treatment. Australas Psychiatr 13:80–82CrossRefGoogle Scholar
  124. 124.
    Stollberger C, Huber JO, Finsterer J (2005) Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 20:243–251PubMedCrossRefGoogle Scholar
  125. 125.
    Su KP, Lane HY, Chuang CL, Chen KP, Shen WW (2004) Olanzapine-induced QTc prolongation in a patient with Wolff–Parkinson–White syndrome. Schizophr Res 66:191–192PubMedCrossRefGoogle Scholar
  126. 126.
    Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F (1997) Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 42:335–339PubMedGoogle Scholar
  127. 127.
    Trenton A, Currier G, Zwemer F (2003) Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 17:307–324PubMedCrossRefGoogle Scholar
  128. 128.
    Varley CK (2000) Sudden death of a child treated with imipramine. Case study. J Child Adolesc Psychopharmacol 10:321–325PubMedGoogle Scholar
  129. 129.
    Varley CK, McClellan J (1997) Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatr 36:390–394CrossRefGoogle Scholar
  130. 130.
    Varma S, Achan K (1999) Dysrhythmia associated with clozapine. Aust NZ J Psychiatr 33:118–119CrossRefGoogle Scholar
  131. 131.
    Varriale P (2001) Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med 161:612PubMedCrossRefGoogle Scholar
  132. 132.
    Vieweg WV, Schneider RK, Wood MA (2005) Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 112:318–322PubMedCrossRefGoogle Scholar
  133. 133.
    Ward OC (1964) A New Familial Cardiac Syndrome In Children. J Ir Med Assoc 54:103–106PubMedGoogle Scholar
  134. 134.
    Weizman A, Weitz R, Szekely GA, Tyano S, Belmaker RH (1984) Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. J Am Acad Child Psychiatr 23:295–298CrossRefGoogle Scholar
  135. 135.
    Welch R, Chue P (2000) Antipsychotic agents and QT changes. J Psychiatr Neurosci 25:154–160Google Scholar
  136. 136.
    Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729–740PubMedCrossRefGoogle Scholar
  137. 137.
    Wernicke JF, Kratochvil CJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatr 63(Suppl 12):50–55Google Scholar
  138. 138.
    Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A (1996) Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatr 35:1491–1501CrossRefGoogle Scholar
  139. 139.
    Wilens TE, Biederman J, March JS, Wolkow R, Fine CS, Millstein RB, Faraone SV, Geller D, Spencer TJ (1999) Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatr 38:573–577CrossRefGoogle Scholar
  140. 140.
    Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC (2006) QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatr 163:325PubMedCrossRefGoogle Scholar
  141. 141.
    Yerrabolu M, Prabhudesai S, Tawam M, Winter L, Kamalesh M (2000) Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2:10–12PubMedGoogle Scholar
  142. 142.
    Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000) Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025–1030PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  1. 1.Department of Paediatric CardiologyOur Lady’s Hospital for Sick ChildrenCrumlinDublin 12Ireland
  2. 2.Department of Child and Adolescent PsychiatryOur Lady’s Hospital for Sick ChildrenCrumlinIreland

Personalised recommendations